Pemazyre (pemigatinib)

pCPA File Number: 23108

Negotiation Status:

Under consideration for negotiation

Indication(s):

For the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a FGFR2 fusion or other rearrangement.

Sponsor/Manufacturer:

Incyte Biosciences Canada Corporation

CDA-AMC Project Number:

PC0391-000

pCPA Engagement Letter Issued:

Not Applicable

Negotiation Process Concluded:

Not Applicable